| Name | Title | Contact Details |
|---|
Achieve is a specialty pharmaceutical company committed to advancing cytisine as a widely available treatment option to help people battling nicotine addiction.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.
Morphosys USA, Inc. is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.